Adam Sperling, MD, PhD

Can't wait.

@paralkarlab.bsky.social
Hello, since you are a hematology/oncology influencer, could you re-post my thing about the Myeloid Workshop being on despite ASH not getting it up on the website? Thank you!

Congrats @oawlab.bsky.social! Well deserved!

Molecular and cellular dynamics of measurable residual disease progression in myelodysplastic syndromes Cancer relapse after treatment invariably proceeds from the persistence and progression of measurable residual disease (MRD), an ultrasmall malignant population. Despite the poor prognostic impact est...

Congrats to Yu-Hsiang Chen, Pavan Bachireddy, and team at @mdanderson.bsky.social for getting this important work out. By understanding how MRD cells escape therapy at a more basic level hopefully we can eventually cure more patients with MDS. www.biorxiv.org/content/10.1...

Journalist here

I’m interested in talking to a federal agency scientist who was fired, then rehired. I can keep you anonymous. I’m on Signal ginnyg.04

Reposts are appreciated!

Anthony Letai, MD, PhD

Congratulations to Anthony Letai, MD, PhD, on being named the new director of the National Cancer Institute. His appointment is a testament to our continuing commitment to innovation and collaboration.

Learn more: bit.ly/4pRWiZy

Rapid epigenomic classification of acute leukemia - Nature Genetics The authors present a molecular classification of acute leukemia using 5-methylcytosine signatures, together with a neural network-based classifier for clinical use.

Epigenetic diagnosis of acute leukemia within two hours from sample receipt 🚀

Very happy to share the results of a great collaboration between @hovestadt.bsky.social and Griffin Labs, I co-led with @sbenfatto.bsky.social, published today in @natgenet.nature.com
📄 www.nature.com/articles/s41...
🧵1/n

Dr. Rashidian from @danafarbernews.bsky.social presenting his work at the 2025 @myeloma-society.bsky.social meeting.

Awesome! Congrats. What a cool story.

Horrible!

Alice T. Shaw named Chair of Department of Medical Oncology at Dana-Farber Cancer Institute | Dana-Farber Cancer Institute Alice T. Shaw, MD, PhD, was named Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute, in an announcement today.

Please join us in congratulating Alice Shaw, MD, PhD, on being named our next Chair of the Department of Medical Oncology.

Learn more: bit.ly/45wiiQ6

Exciting!

What an awesome meeting. Was great to catch up with everyone.

It's my first #newPI roll call on BlueSky! Calling all new #cancer PIs who just started or who are about to start their labs! Please say hi and what you work on so I can follow you if I don't already! 😃

The Myeloid Workshop is back in ASH! Please contact the organizers if you have an exciting story that will not be out by December they are: Zuzana Tothova ,
@ernstlaboratory.bsky.social
@steidluli.bsky.social
@ericpietras.bsky.social
@kathrinbernt.bsky.social
@gritsmanlab.bsky.social

Congrats!

Super interesting. Congrats on getting this out.

And here it is! Our study in clonal hematopoiesis and Alzheimer’s disease — product of 5 years’ gestation. urldefense.proofpoint.com/v2/url?u=htt...

Major Regulatory Milestone in MM: In response to an application by I2TEAMM and IMFmyeloma, the European Medicines Agency has officially endorsed MRD as an early endpoint in clinical trials for Myeloma. This marks a transformative step forward in drug development !! @vincentrk.bsky.social

Was this article written by GSK?

We are proud to announce that the International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma has been published by the Journal of Clinical Oncology! ascopubs.org/doi/10.1200/...

Wow. That's insane. How did you respond?

I think it's more insidious that just not understanding drug discovery. This mindset among SV types is part of what justifies their recent destruction of the NIH. If AI will cure disease in 10 years, who needs the universities and research institutes?

As someone directly affected by this, let me be clear:

I'd rather lose my job because Harvard chose to fight than keep my job and see a generation of white supremacists parade its corpse around like a war trophy.

Embarrassing...

Looks cold

Yuxin Liu, MD

Meet Yuxin Liu, MD, who treats patients with multiple myeloma and other plasma cell disorders. Her clinical research focuses on novel therapies in newly diagnosed and relapsed multiple myeloma. https://bit.ly/3FljInk

Diet plays a pivotal role in cancer care, yet clear guidelines remain scarce. Dr. Urvi A. Shah explores the evidence, challenges, and need for more robust dietary intervention trials in oncology. ascopost.com/news/march-2...

#OncologyResearch #CancerCare

Multiple myeloma is a terrible disease.